Comparison of Two Assays to Determine Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis in relation to Other Chronic Inflammatory Rheumatic Diseases: Assaying Anti-Modified Citrullinated Vimentin Antibodies Adds Value to Second-Generation Anti-Citrullinated Cyclic Peptides Testing

Table 3

Utility values of anti-CCP2, anti-MCV, or any of these assays in rheumatoid arthritis in comparison with clinically healthy subjects (CHS).

Utility values of the assays for anti-CCP2 and anti-MCV results	Anti-CCP2	Anti-MCV	Anti-CCP2 or anti-MCV
Sensitivity % (95% CI)	66 (58–74)	81 (73–87)	85 (78–91)
Specificity % (95% CI)	94 (84–99)	94 (84–99)	94 (84–99)
Positive predictive value % (95% CI)	97 (91–99)	97 (93–99)	97 (93–99)
Negative predictive value % (95% CI)	51 (41–61)	65 (53–75)	70 (58–81)
LR+	11.69 (3.87–35.32)	14.31 (4.75–43.07)	15.05 (5–45.28)
LR−	0.36 (0.28–0.46)	0.20 (0.14–0.28)	0.16 (0.11–0.23)
Prevalence	73 (66–79)	73 (66–79)	73 (66–79)

LR+: positive likelihood ratio; LR−: negative likelihood ratio.